数据链接：
官方服务：
资源简介：
Number of assets in next-generation obesity R&D pipeline worldwide as of 2024, by mechanism of action
应用场景：
相关数据集
Interaction of gut microbiota and anti-obesity drugs in diet induced obesity model. mouse gut metagenome
Although study that drugs modulated gut microbiota often reported, the effect of anti-obesity drug on gut microbiota were unclear. This study focused on relationship between anti-obesity drugs and gut
NIAID Data Ecosystem80
pH-Responsive Micelle Sequestrant Polymers Inhibit Fat Absorption
Current antiobesity therapeutics are associated with side effects and/or poor long-term patient compliance, necessitating development of more efficacious and safer alternatives. Herein, we designed an
NIAID Data Ecosystem60
Discovery of a Human Neuromedin U Receptor 1‑Selective Hexapeptide Agonist with Enhanced Serum Stability
Neuromedin U (NMU) activates two NMU receptors (NMUR1 and NMUR2) and is a useful antiobesity drug lead. We report discovery of a hexapeptide agonist, 2-thienylacetyl-Trp1-Phe(4-F)2-Arg3-Pro4-Arg5-Asn
Figshare2017-06-02 更新40
Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid‑1 (CB 1 R) Receptor with Reduced Lipophilicity
In the present report, we describe the synthesis and structure–activity relationships of novel “four-arm” dihydropyrazoline compounds designed as peripherally restricted antagonists of cannabinoid-1 r
NIAID Data Ecosystem60
Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure–Activity Relationships of Novel 1‑(Imidazo[1,2‑ a ]pyridin-6-yl)pyridin-2(1 H )‑one Derivatives
Aiming to discover melanin-concentrating hormone receptor 1 (MCHR1) antagonists with improved safety profiles, we hypothesized that the aliphatic amine employed in most antagonists reported to date co
NIAID Data Ecosystem50
